Q: Hi Folks. This is really not a question but rather an addition to the discussion. On July 11 RBC came out with a report downgrading HCG from market perform to under perform. It seemed quite well reasoned to me and made the point that RBC now sees HCG as a steady growth company rather than a high growth company. They think this problem is specific to HCG and not industry wide. They think HCG can deliver double digit EPS growth long term but in the near term it is likely to be low to mid single digit.
Ross
Ross